|Articles|April 15, 2003
- BioPharm International-04-01-2003
- Volume 16
- Issue 4
Using Peptide Maps as Identity and Purity Tests for Lot Release Testing of Recombinant Therapeutic Proteins
by John Dougherty, Eli Lilly and Company, Rohin Mhatre, Biogen, Inc., and Stephen Moore, CDER FDA and biopharmaceutical industry stakeholders reach consensus on critical issues related to the use of peptide maps as identity tests for proteins and on their usefulness for lot release tests. The results of that discussion are presented here.
Advertisement
Articles in this issue
over 22 years ago
Virus Inactivation in the 1990s and into the 21st Centuryover 22 years ago
Getting Ready for Risk-Based GMPsover 22 years ago
GMP Issues: Breaking Groundover 22 years ago
Guest Editorial: Benchmarking Biotechover 22 years ago
Optimized Nutrient Additives for Fed-Batch Culturesover 22 years ago
Inside Washington: GMP Progress ReportNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4